Pharma Marketing Network

Vioxx Withdrawal and the "Me-Too Drug Domino Effect" OpEd by John Mack ...

This article summarizes the results of a recent Pharma Marketing News Survey on this topic.

The California legislature recently passed SB 1765 (aka, 'fair drug marketing bill'), which requires pharma companies to comply with PhRMA and OIG Guidelines. this article summarizes the provisions of this bill, which is currently awaiting signature by Governor Schwarzenegger.

Richard B. Vanderveer, Ph.D., CEO of the global pharmaceutical marketing and research firm V2 GfK, presents strategies for enhanced physician targeting and segmentation.

This article summarizes different aspects of this latest innovation in portability and performance and how they could be used to increase sales force effectiveness in both the primary care and hospital-based environments.

This article provides insight from experts such as Mark Bard, President of Manhattan Research and David Kibbe, M.D., Director, Healthcare Information Technology, American Academy of Family Physicians (AAFP), on the impact of new technologies at the point of care on pharmaceutical sales and marketing.

Dear Reader, Welcome to the October 2004 archive of Pharma Marketing News. Vol. 3,...

Vol. 3, No. 9: October 2004 - PREVIEW The following are summaries of articles planned for the upcoming...

Featured Conference Direct to Consumer Strategies for Medical Devices September 30 - October 1, 2004...

Off-label usage of drugs and medical devices accounts for a large percentage of profits yet also presents a minefield of potential legal, regulatory, ethical, and financial problems. To make matters worse, the regulatory and legal landscape has become more varied and confusing in recent years as organizations such as the DOJ, the OIG, and more have become involved. Here’s a chance for you to learn everything you need to know about this difficult topic in one easy stop.